Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arcus Biosciences (RCUS)

Arcus Biosciences signs up to $250 million secured term loan with Hercules Capital

Neutral Impact 4 of 5 financing Written later

Arcus Biosciences entered a Loan and Security Agreement with Hercules Capital on August 27, 2024, providing a secured term loan facility of up to $250.0 million. Only $50.0 million was funded at closing, with the rest available under later tranches at the company's option or the lenders' option, and the loans are secured by substantially all company assets.

Key points

  • $50.0 million funded on August 27, 2024; up to $150.0 million more available at the company's option through March 15, 2026, and a further $100.0 million at the lenders' option
  • Interest at the greater of Prime Rate plus 1.95% or 10.45%; interest-only payments until September 1, 2028; maturity September 1, 2029
  • Financial covenant requires Qualified Cash of at least 50% of outstanding principal when market capitalization is at or below $1.20 billion, with reductions upon milestones

The filing

CompanyArcus Biosciences (RCUS)
Form8-K, current report
Filed with the SECAug 27, 2024, 4:12 PM ET
Accession number0001724521-24-000144

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:49 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 27, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.